The CLEVER Study - Coreg And Left Ventricular Mass Regression
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the effects of COREG MR (carvedilol modified release
formulation) to atenolol on indices of left ventricular dimensions when added to standardized
angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone.
Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The
primary endpoint will be the change in left ventricular mass index (LVMI) characterized by
magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints
include the change in LV (left ventricular) mass, LV wall thickness, diastolic left
ventricular filling parameters, and left ventricular ejection fraction by echocardiographic
methods at Treatment Month 12. Composite outcomes and individual event data will also be
evaluated by treatment group.